Orphazyme A/S Stock price

Equities

ORPHA

DK0062502894

Biotechnology & Medical Research

Delayed Nasdaq Copenhagen 11:35:18 2024-03-27 am EDT 5-day change 1st Jan Change
1,200 DKK +0.84% Intraday chart for Orphazyme A/S -0.84% -9.79%
Sales 2021 36.19 250.67 Sales 2022 - Capitalization 31.07M 215M
Net income 2021 -627M -4.34B Net income 2022 26M 180M EV / Sales 2021 14,850,643 x
Net cash position 2021 62.29M 431M Net cash position 2022 42.46M 294M EV / Sales 2022 -
P/E ratio 2021
-0.96 x
P/E ratio 2022
1.19 x
Employees 1
Yield 2021 *
-
Yield 2022
-
Free-Float 59.56%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.84%
1 week-0.84%
Current month-5.87%
1 month-6.25%
3 months-11.78%
6 months+14.27%
Current year-9.79%
More quotes
1 week
1 101.00
Extreme 1101
1 240.00
1 month
1 101.00
Extreme 1101
1 324.00
Current year
850.00
Extreme 850
1 400.00
1 year
407.00
Extreme 407
5 370.00
3 years
407.00
Extreme 407
109 100.00
5 years
407.00
Extreme 407
137 500.00
10 years
407.00
Extreme 407
137 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 23-05-16
Members of the board TitleAgeSince
Director/Board Member 43 23-05-16
Chairman 53 23-05-16
Chief Executive Officer 46 23-05-16
More insiders
Date Price Change Volume
24-03-27 1,200 +0.84% 40
24-03-26 1,190 +0.03% 38
24-03-25 1,189 -0.88% 70
24-03-22 1,200 -0.83% 44
24-03-21 1,210 +3.42% 36

Delayed Quote Nasdaq Copenhagen, March 27, 2024 at 11:35 am EDT

More quotes
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company's candidate, arimoclomol, stimulates the production of the cells? protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells? recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.
More about the company
  1. Stock
  2. Equities
  3. Stock Orphazyme A/S - Nasdaq Copenhagen